Research Documentation

Technical specifications, evidence base, and collaboration framework for scientists, clinicians, and laboratory partners engaging with the Cytotrophics program.

Evidence Base: Bomb Calorimetry Inadequacies

The following represents the category structure of the peer-reviewed evidence documenting the inadequacies of bomb calorimetry as a measurement tool for human metabolism. This is an active and expanding bibliography.

Digestibility and Whole Food Matrix Effects

Multiple controlled studies demonstrate systematic differences between caloric values predicted by bomb calorimetry and actual energy available to human subjects. The nut studies (Baer et al., 2012; Novotny et al., 2012; Gebauer et al., 2016) are the most thoroughly documented: whole almonds, walnuts, and pistachios consistently yield 20–32% fewer usable calories than Atwater values predict, due to intact cell wall barriers that resist human enzymatic digestion. This is not a measurement error. It is a demonstration that the measurement tool is wrong for the purpose.

Individual Variation in Energy Extraction

Studies using doubly labeled water (the gold standard for total energy expenditure) consistently document 30–50% inter-individual variation in energy extraction from identical diets under controlled conditions. This variation is not explainable by measurement error, compliance differences, or genetic outliers — it represents normal biological range. A measurement system that ignores normal biological range is not a valid measurement system for individual prescription.

The Thermic Effect of Food

The thermic effect of protein (25–30% of caloric value), carbohydrate (5–10%), and fat (2–3%) is well-documented and has been for decades. The failure to incorporate these known values into standard caloric labeling is not a scientific limitation — it is a policy choice that prioritizes label simplicity over accuracy. The caloric system knowingly presents inaccurate numbers.

Gut Microbiome and Energy Metabolism

The relationship between gut microbiome composition and energy extraction efficiency is an active and rapidly expanding research field. Key findings: (1) Bacteroidetes-dominant versus Firmicutes-dominant microbiomes show measurable differences in SCFA production and energy harvest; (2) germ-free mouse models demonstrate dramatically different adiposity outcomes on identical diets compared to conventionally colonized mice; (3) human microbiome transplant studies show metabolic phenotype transfer. The microbiome is not a footnote to energy metabolism — it is a central variable that the caloric system does not model.

Dietary Fiber Miscategorization

The 4 kcal/gram assignment to fiber (matching carbohydrates) reflects bomb calorimetry combustion values, not human metabolic availability. Human small intestine absorbs negligible fiber directly. Colonic bacteria ferment soluble fiber into SCFAs (acetate, propionate, butyrate), of which humans absorb approximately 1.5–2.5 kcal/gram depending on microbiome composition — not 4. The label is wrong by approximately a factor of two in the worst case, consistently, for a macronutrient category that constitutes a significant portion of total dietary intake in high-fiber diets.

Phenotyping Protocols

The Cytotrophics PT system requires standardized measurement protocols for each phenotyping dimension. The following specifications represent current working protocol; all are subject to refinement through the Excreta Diagnostics validation loop.

PT-1: Digestive Efficiency Assessment

• Salivary amylase activity: Standard salivary amylase assay (spectrophotometric, starch-iodine method); copy number variation via qPCR for AMY1 gene
• Pancreatic elastase: Fecal elastase ELISA (already clinically validated, reference ranges established)
• Fat absorption coefficient: 72-hour fecal fat collection during controlled dietary intake; gravimetric analysis
• Whole food matrix test: Controlled almond challenge (50g whole vs. 50g blanched, ground); urinary nitrogen and fecal fat comparison over 48-hour period

PT-2: Microbiome Functional Phenotype

• Compositional profiling: 16S rRNA sequencing (V3-V4 region, minimum 50,000 reads); OTU clustering at 97% similarity
• Functional profiling: Shotgun metagenomics for pathway abundance; PICRUSt2 for functional prediction where shotgun not available
• SCFA quantification: Fecal SCFA profile via GC-FID (acetate, propionate, butyrate, isobutyrate, valerate, isovalerate); express as molar ratios and absolute concentrations
• TMAO production: Plasma TMAO following 300mg L-carnitine challenge; fecal TMA measurement

PT-3 through PT-7

Full protocols for insulin sensitivity phenotyping (mixed-meal tolerance test, HOMA-IR, continuous glucose monitoring analysis), fat metabolism variant characterization (lipoprotein electrophoresis, apoE genotyping, bile acid panel), micronutrient absorption profiling (mineral balance studies, isotopic labeling where appropriate), inflammatory baseline assessment (fecal calprotectin, plasma cytokine panel, food challenge protocols), and circadian metabolic phenotyping (cortisol awakening response, glucose tolerance by time of day, dim light melatonin onset) are available in the working protocol document.

Excreta Analysis Layers — Technical Specifications

The ten-layer Excreta Diagnostics analysis framework, with technology specifications for each layer:

Collaboration Framework

The Cytotrophics program is structured as an open, cooperative research effort. We do not gatekeep the framework, the protocols, or the evidence base. The goal is the fastest possible replacement of bomb calorimetry with an adequate measurement system — proprietary gatekeeping is incompatible with that goal.

For Clinicians

The PT framework can be applied within existing clinical workflows using currently available testing. A minimum viable phenotype characterization can be assembled from: salivary amylase (research), fecal elastase (clinically available), gut microbiome sequencing (commercially available), basic lipid panel with apoE genotyping, fasting insulin and HOMA-IR, and fecal calprotectin. This is not a complete PT characterization, but it is a beginning that is available now.

For Laboratory Partners

We are seeking laboratory partners for the Excreta Diagnostics Phase 1 wastewater surveillance proof-of-concept. Requirements: capacity for Layer 1–6 analysis on composite wastewater samples, willingness to operate under open-data protocols, geographic diversity. If your laboratory has relevant capabilities, the contact mechanism is below.

For Wastewater Treatment Facilities

The Phase 1 deployment requires partnerships with 20 facilities across diverse geographies. We provide: standardized sampling protocols, shipping and preservation guidance, all analytical costs, and the full dataset from your facility's service area. You provide: access to composite samples at agreed sampling frequency and facility geographic and operational metadata. No individual data is involved at any stage.

For Researchers

The Cytotrophics framework, PT system, and Excreta Diagnostics layer specifications are available for use and extension under open research terms. We ask for attribution and that any refinements or extensions be shared back to the common pool. The enemy is the dead tree. We are not competing with each other.

Contact and Collaboration

This work is in active development. The framework is specified. The protocols are drafts subject to refinement. The evidence base is real and citable. What we need is engagement from people who can contribute to any part of the work: laboratory capacity, clinical implementation, wastewater facility partnerships, statistical methodology, regulatory navigation, or simply serious engagement with the ideas.

Primary contact: James Allen Clow — cytotrophics.com